From: 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment
Genitourinary (frequency, urgency, pain)
G2: 3 (12%)
G1: 6 (24%)
Gastrointestinal (rectal pain)
G2: 1 (4%)
G1: 2 (8%)